Bjork Elisabeth sold $2.0M of PHVS

Bjork Elisabeth sold 52,500 shares of Pharvaris N.V. (PHVS) at $37.89 ($1.99M total) on 2026-09-17.

Original reporting
SEC EDGAR · Bjork Elisabeth
Published Sep 21, 2026, 7:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Bearish
medium confidence
Mentioned
$PHVS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSBearishLow
01

Why it matters

The director's sale reduces insider ownership, possibly affecting investor confidence.

02

Market read

Routine insider sale with modest size; limited trading impact.

03

What to watch

Potential upcoming clinical data could offset negative perception.

Relevance 6/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$PHVSBearishMedium confidence
Context

Director Bjork Elisabeth sold 52,500 shares for $1.99M, reducing her stake to 15,167 shares.

Expected impact

Potential short-term pressure on PHVS, limited to a few percent.

Evidence & confidence

Form 4 filing is primary source; sale amount is notable but not material enough to drive large price move.

Market effects

May raise concerns for biotech sector insiders but limited impact.

No broader regional effect.

Minimal global relevance.

Counterpoint

Insider may be diversifying; sale does not reflect company fundamentals.

Key entities

  • Pharvaris N.V.

    Biotech company listed on Nasdaq under ticker PHVS.

  • Bjork Elisabeth

    Director of Pharvaris N.V. who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.